BURLINGTON, Mass. – May 26, 2016 – inVentiv Health, Inc., a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced that David Southwell has been elected to its Board of Directors, effective immediately. Mr. Southwell will also serve as the Chairman of the Audit Committee.
Mr. Southwell is currently President and Chief Executive officer of Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a development-stage company focused on diseases of the eye. Before joining Inotek, he served as the Executive Vice President and Chief Financial Officer of Human Genome Sciences, Inc., prior to the acquisition of the company by GlaxoSmithKline plc. Mr. Southwell was also the Executive Vice President and Chief Financial Officer of Sepracor Inc. for 14 years. Prior to his extensive tenure in the biopharmaceutical sector, he was a Vice President at Lehman Brothers.
"David Southwell will add significant value as a member of our Board of Directors, drawing on his decades of experience in the biopharmaceutical sector and his financial acumen," said Michael Bell, inVentiv Health Chairman and CEO. "His fluency in both complex science and specialty pharmaceuticals will be particularly relevant as we help clients navigate an increasingly complex marketplace."
Mr. Southwell currently holds board memberships with three public companies: PTC Therapeutics, Inc. (NASDAQ: PTCT), Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) and THL Credit, Inc. (NASDAQ: TRCD). He also previously served on the board of Human Genome Sciences, Inc., prior to his appointment as CFO.
"Given rapidly changing market dynamics, it's an exciting time to join the Board at inVentiv," said Mr. Southwell. "The company's combination of leading clinical capabilities and comprehensive commercialization services offers unique benefits to clients seeking to expedite the delivery of important medicines. I look forward to working with the management team."
Mr. Southwell holds an MBA from the Tuck School of Business Administration, where he serves on the Board of Overseers, and a BA from Rice University.